share_log

Autolus Therapeutics Raises $100M Via Equity

Autolus Therapeutics Raises $100M Via Equity

Autolus治疗公司通过股权筹集1亿美元
Benzinga Real-time News ·  2021/02/10 19:59
  • Autolus Therapeutics PLC (NASDAQ: AUTL) prices an underwritten public offering in the U.S. of 14.3 million American Depositary Shares (ADS) representing 14.3 million ordinary shares at $7 per ADS, for total gross proceeds of approximately $100 million. Underwriters have an option to purchase up to an additional 2.1 million ADSs.
  • The offering is expected to close on February 12.
  • J.P. Morgan and Wells Fargo Securities are acting as joint book-runners for the offering.
  • Autolus did not mention the use for the proceeds raised. Still, last month, it prioritized the development of AUTO1 and thus planned to cut headcount by approximately 20% resulting in annualized savings of $15 million. AUTO1 is under development for adult acute lymphoblastic leukemia, with full data from the AUTO1-AL1 study expected in 2022.
  • Autolus plans to seek a partner for the AUTO3 program, its CAR T product candidate for relapsed/refractory diffuse large B cell lymphoma, ahead of progressing into the next phase of development.
  • Price Action: AUTL slid 2% at $7.35 during the premarket trading on the last check Wednesday.
  • Autolus Treateutics PLC(纳斯达克：AUTL) 为承销的公开发行定价在美国，1,430万股美国存托股份(ADS)相当于1,430万股普通股，每股ADS 7美元，总收益约为1亿美元。承销商有权再购买至多210万只美国存托凭证。
  • 此次发行预计将于2月12日结束。
  • 摩根大通(J.P.Morgan)和富国银行证券(Wells Fargo Securities)将担任此次发行的联合簿记管理人。
  • Autolus没有提到募集资金的用途。尽管如此，上个月，它还是优先考虑了AUTO1的开发，因此计划裁员大约20%，年化节省1500万美元。AUTO1正在开发用于成人急性淋巴细胞白血病的AUTO1，预计2022年将有AUTO1-AL1研究的完整数据。
  • Autolus计划在进入下一阶段开发之前，为其治疗复发/难治性弥漫性大B细胞淋巴瘤的CAR T产品候选AUTO3计划寻找合作伙伴。
  • 价格行动：在周三最后一次检查的盘前交易中，AUTL下跌2%，至7.35美元。

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发